Caladrius Biosciences, Inc. focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia.
Market Cap | 28.688 Million | Shares Outstanding | 7.86 Million | Avg 30-day Volume | 17.107 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.29 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -26.556 Million |
Price to Book Value | 0.0 | Operating Margin | 0.0 | Enterprise Value | 0 |
Current Ratio | 21.265 | EPS Growth | 0.057 | Quick Ratio | 20.997 |
1 Yr BETA | -1.9183 | 52-week High/Low | 9.38 / 0.4 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -152.1251 | Altman Z-Score | 0.0 | Free Cash Flow to Firm | -19.696 Million |
Earnings Report | 2023-03-21 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
MAZZO DAVID J CHIEF EXECUTIVE OFFICER |
|
96,543 | 2023-01-13 | 3 |
|
30,090 | 2023-01-09 | 1 | |
|
20,000 | 2023-01-09 | 1 | |
|
39,200 | 2023-01-09 | 1 | |
|
1,191,144 | 2023-01-09 | 1 | |
|
29,934 | 2023-01-09 | 1 | |
|
29,721 | 2023-01-09 | 1 | |
BUCK KRISTEN K EVP, R&D AND CMO |
|
81,158 | 2023-01-09 | 1 |
SLACK DAVID W. PRESIDENT & CBO |
|
32,642 | 2023-01-09 | 1 |
GIROLAMO TODD C CLO, SVP OF CORP DEV |
|
160,827 | 2022-01-13 | 0 |
|
223,459 | 2022-01-10 | 0 | |
|
149,190 | 2022-01-10 | 0 | |
|
209,753 | 2022-01-10 | 0 | |
|
182,635 | 2022-01-10 | 0 | |
TALAMO JOSEPH SVP AND CFO |
|
59,644 | 2020-01-13 | 0 |
LOSORDO DOUGLAS W SEE REMARKS |
|
130,406 | 2020-01-13 | 0 |
|
No longer subject to file | 2017-05-18 | 0 | |
|
1,059,322 | 2017-03-22 | 0 | |
|
7,177 | 2017-01-09 | 0 | |
|
191,523 | 2017-01-09 | 0 | |
|
1,271,186 | 2016-09-14 | 0 | |
|
393,784 | 2016-06-22 | 0 | |
VATERS ROBERT S PRESIDENT & CFO |
|
228,750 | 2015-08-12 | 0 |
|
88,531 | 2015-06-02 | 0 | |
SMITH ROBIN L EXECUTIVE CHAIR OF THE BOARD |
|
347,285 | 2015-06-02 | 0 |
|
10,000 | 2015-06-02 | 0 | |
VACZY CATHERINE M GENERAL COUNSEL |
|
71,234 | 2015-04-13 | 0 |
RIMASIA CAPITAL PARTNERS MANAGER, LTD. RIMASIA CAPITAL PARTNERS, L.P. RIMASIA CAPITAL PARTNERS GP, L.P. |
|
2,222,988 | 2015-01-02 | 0 |
DICKEY ROBERT IV CHIEF FINANCIAL OFFICER |
|
12,066 | 2014-12-31 | 0 |
POTTER STEPHEN W EXECUTIVE VICE PRESIDENT |
|
14,016 | 2014-12-31 | 0 |
KEIRSTEAD HANS SEE REMARKS |
|
0 | 2014-05-09 | 0 |
DILLMAN ROBERT SEE REMARKS |
|
0 | 2014-05-09 | 0 |
MAY LARRY ALAN CHIEF FINANCIAL OFFICER |
|
0 | 2013-01-02 | 0 |
|
0 | 2012-06-29 | 0 | |
SCHMIEG MARTIN E VICE PRESIDENT- CORPORATE DEV |
|
0 | 2012-06-25 | 0 |
SACKNER-BERNSTEIN JONATHAN VP CLINICAL DEV & REG AFFAIRS |
|
0 | 2012-04-02 | 0 |
RIMASIA CAPITAL PARTNERS, L.P. RIMASIA CAPITAL PARTNERS GP, L.P. |
|
22,529,874 | 2012-01-12 | 0 |
|
22,529,874 | 2012-01-12 | 0 | |
SHI MINGSHENG SEE REMARKS |
|
0 | 2012-01-04 | 0 |
KOLBERT JASON SEE REMARKS |
|
0 | 2012-01-04 | 0 |
HARRIS ALAN G SEE REMARKS |
|
0 | 2011-04-04 | 0 |
ZHANG IAN SEE REMARKS |
|
0 | 2011-04-04 | 0 |
ZHANG JIAN M SEE REMARKS |
|
0 | 2010-06-09 | 0 |
SALERNO ANTHONY SEE REMARKS |
|
0 | 2010-06-09 | 0 |
|
3,047,432 | 2009-12-30 | 0 | |
DUIGNAN CHRISTOPHER C VICE PRESIDENT, FINANCE |
|
0 | 2009-11-30 | 0 |
SAMUELS LEPORE TERESA LINN VP OF SALES AND MARKETING |
|
0 | 2009-10-29 | 0 |
SOUTHPOINT CAPITAL ADVISORS LP |
|
No longer subject to file | 2009-06-18 | 0 |
WEINREB MARK PRESIDENT |
|
0 | 2009-05-21 | 0 |
|
0 | 2009-05-21 | 0 | |
ENHANCE BIOMEDICAL HOLDINGS LTD |
|
4,000,000 | 2009-04-09 | 0 |
|
0 | 2008-12-31 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-01-17 17:05:25 -0500 | 2023-01-13 | F | 397 | $3.65 | d | 96,543 | direct | 0.6924 | 4.5874 | 7.0398 | 5 | 0.0 | 1 | |||
2023-01-12 16:02:08 -0500 | 2023-01-11 | F | 1,030 | $3.20 | d | 96,940 | direct | -0.8493 | -0.274 | 0.0 | 1 | -5.0411 | 3 | |||
2023-01-11 16:03:09 -0500 | 2023-01-10 | F | 512 | $3.20 | d | 35,823 | direct | 1.9838 | -2.6264 | 1.9838 | 2 | -3.1573 | 4 | |||
2023-01-11 16:07:53 -0500 | 2023-01-10 | F | 3,470 | $3.20 | d | 97,970 | direct | 1.9838 | -2.6264 | 1.9838 | 2 | -3.1573 | 4 | |||
2023-01-11 16:10:05 -0500 | 2023-01-09 | F | 3,358 | $3.00 | d | 20,642 | direct | 1.9838 | -2.6264 | 1.9838 | 2 | -3.1573 | 4 | |||
2023-01-11 16:20:29 -0500 | 2023-01-09 | A | 20,000 | a | 20,000 | direct | 1.9838 | -2.6264 | 1.9838 | 2 | -3.1573 | 4 | ||||
2023-01-11 16:18:50 -0500 | 2023-01-09 | A | 20,000 | a | 30,090 | direct | 1.9838 | -2.6264 | 1.9838 | 2 | -3.1573 | 4 | ||||
2023-01-11 16:17:24 -0500 | 2023-01-09 | A | 20,000 | a | 20,000 | direct | 1.9838 | -2.6264 | 1.9838 | 2 | -3.1573 | 4 | ||||
2023-01-11 16:15:48 -0500 | 2023-01-09 | A | 20,000 | a | 29,721 | direct | 1.9838 | -2.6264 | 1.9838 | 2 | -3.1573 | 4 | ||||
2023-01-11 16:13:54 -0500 | 2023-01-09 | A | 20,000 | a | 29,934 | direct | 1.9838 | -2.6264 | 1.9838 | 2 | -3.1573 | 4 | ||||
2023-01-11 16:12:19 -0500 | 2023-01-09 | A | 20,000 | a | 39,200 | direct | 1.9838 | -2.6264 | 1.9838 | 2 | -3.1573 | 4 | ||||
2023-01-11 16:10:05 -0500 | 2023-01-09 | A | 12,000 | a | 12,000 | direct | ||||||||||
2023-01-11 16:03:09 -0500 | 2023-01-09 | A | 18,000 | a | 38,482 | direct | 1.9838 | -2.6264 | 1.9838 | 2 | -3.1573 | 4 | ||||
2023-01-11 16:10:05 -0500 | 2023-01-09 | A | 24,000 | a | 24,000 | direct | 1.9838 | -2.6264 | 1.9838 | 2 | -3.1573 | 4 | ||||
2023-01-11 16:07:53 -0500 | 2023-01-09 | A | 30,000 | a | 30,000 | direct | ||||||||||
2023-01-11 16:07:53 -0500 | 2023-01-09 | F | 7,845 | $3.00 | d | 101,440 | direct | 1.9838 | -2.6264 | 1.9838 | 2 | -3.1573 | 4 | |||
2023-01-11 16:07:53 -0500 | 2023-01-09 | A | 60,000 | a | 109,285 | direct | 1.9838 | -2.6264 | 1.9838 | 2 | -3.1573 | 4 | ||||
2023-01-11 16:03:09 -0500 | 2023-01-09 | A | 9,000 | a | 9,000 | direct | ||||||||||
2023-01-11 16:03:09 -0500 | 2023-01-09 | F | 2,147 | $3.00 | d | 36,335 | direct | 1.9838 | -2.6264 | 1.9838 | 2 | -3.1573 | 4 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
LISATA THERAPEUTICS INC LSTA | 2023-02-06 16:45:03 UTC | 1.1582 | 3.4118 | 70000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-06 16:15:03 UTC | 1.1582 | 3.4118 | 70000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-06 15:45:04 UTC | 1.1582 | 3.4118 | 70000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-06 15:15:03 UTC | 1.1582 | 3.4118 | 70000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-06 14:45:04 UTC | 1.1625 | 3.4075 | 70000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-06 14:15:04 UTC | 1.1625 | 3.4075 | 70000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-06 13:45:03 UTC | 1.1625 | 3.4075 | 70000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-06 13:15:03 UTC | 1.1625 | 3.4075 | 70000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-06 12:45:03 UTC | 1.1625 | 3.4075 | 35000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-03 22:15:03 UTC | 1.1625 | 3.4075 | 65000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-03 21:45:03 UTC | 1.1654 | 3.4046 | 65000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-03 21:15:03 UTC | 1.1654 | 3.4046 | 65000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-03 20:45:06 UTC | 1.1654 | 3.4046 | 65000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-03 20:15:04 UTC | 1.1654 | 3.4046 | 65000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-03 19:45:03 UTC | 1.1654 | 3.4046 | 65000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-03 19:15:04 UTC | 1.1654 | 3.4046 | 65000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-03 18:45:03 UTC | 1.1654 | 3.4046 | 65000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-03 18:15:03 UTC | 1.1654 | 3.4046 | 65000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-03 17:45:03 UTC | 1.1654 | 3.4046 | 65000 |
LISATA THERAPEUTICS INC LSTA | 2023-02-03 17:15:04 UTC | 1.1654 | 3.4046 | 65000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | LSTA | -100.0 shares, $-463.0 | 2022-09-30 | N-PORT |